158 related articles for article (PubMed ID: 10608481)
1. Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro.
Wang JS; Backman JT; Wen X; Taavitsainen P; Neuvonen PJ; Kivistö KT
Pharmacol Toxicol; 1999 Nov; 85(5):201-5. PubMed ID: 10608481
[TBL] [Abstract][Full Text] [Related]
2. Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine.
Isohanni MH; Neuvonen PJ; Olkkola KT
Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):168-72. PubMed ID: 16918719
[TBL] [Abstract][Full Text] [Related]
3. Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans.
Wang JS; Backman JT; Taavitsainen P; Neuvonen PJ; Kivistö KT
Drug Metab Dispos; 2000 Aug; 28(8):959-65. PubMed ID: 10901707
[TBL] [Abstract][Full Text] [Related]
4. Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors.
Murray M; Zhang WV; Edwards RJ
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):388-395. PubMed ID: 29155491
[TBL] [Abstract][Full Text] [Related]
5. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
[TBL] [Abstract][Full Text] [Related]
6. Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes.
Taavitsainen P; Anttila M; Nyman L; Karnani H; Salonen JS; Pelkonen O
Pharmacol Toxicol; 2000 May; 86(5):215-21. PubMed ID: 10862503
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors.
Arlander E; Ekström G; Alm C; Carrillo JA; Bielenstein M; Böttiger Y; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 1998 Nov; 64(5):484-91. PubMed ID: 9834040
[TBL] [Abstract][Full Text] [Related]
8. The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine.
Olkkola KT; Isohanni MH; Hamunen K; Neuvonen PJ
Anesth Analg; 2005 May; 100(5):1352-1356. PubMed ID: 15845683
[TBL] [Abstract][Full Text] [Related]
9. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
Eagling VA; Tjia JF; Back DJ
Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function.
Orlando R; Piccoli P; De Martin S; Padrini R; Floreani M; Palatini P
Clin Pharmacol Ther; 2004 Jan; 75(1):80-8. PubMed ID: 14749694
[TBL] [Abstract][Full Text] [Related]
11. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine.
Eiermann B; Engel G; Johansson I; Zanger UM; Bertilsson L
Br J Clin Pharmacol; 1997 Nov; 44(5):439-46. PubMed ID: 9384460
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract.
Iwata H; Tezuka Y; Kadota S; Hiratsuka A; Watabe T
Drug Metab Dispos; 2004 Dec; 32(12):1351-8. PubMed ID: 15342469
[TBL] [Abstract][Full Text] [Related]
13. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.
Orlando R; Piccoli P; De Martin S; Padrini R; Palatini P
Br J Clin Pharmacol; 2003 Jan; 55(1):86-93. PubMed ID: 12534644
[TBL] [Abstract][Full Text] [Related]
14. Rate-limiting biotransformation of triamterene is mediated by CYP1A2.
Fuhr U; Kober S; Zaigler M; Mutschler E; Spahn-Langguth H
Int J Clin Pharmacol Ther; 2005 Jul; 43(7):327-34. PubMed ID: 16035375
[TBL] [Abstract][Full Text] [Related]
15. Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes.
Yamazaki H; Urano T; Hiroki S; Shimada T
J Toxicol Sci; 1996 Nov; 21(4):215-26. PubMed ID: 8959645
[TBL] [Abstract][Full Text] [Related]
16. In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [N-methyl-14C]-erythromycin.
Riley RJ; Howbrook D
J Pharmacol Toxicol Methods; 1997 Dec; 38(4):189-93. PubMed ID: 9566442
[TBL] [Abstract][Full Text] [Related]
17. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.
Eagling VA; Wiltshire H; Whitcombe IW; Back DJ
Xenobiotica; 2002 Jan; 32(1):1-17. PubMed ID: 11824416
[TBL] [Abstract][Full Text] [Related]
18. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine.
Rasmussen BB; Maënpää J; Pelkonen O; Loft S; Poulsen HE; Lykkesfeldt J; Brøsen K
Br J Clin Pharmacol; 1995 Feb; 39(2):151-9. PubMed ID: 7742153
[TBL] [Abstract][Full Text] [Related]
19. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
Wen X; Wang JS; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
[TBL] [Abstract][Full Text] [Related]
20. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam.
Hesse LM; Venkatakrishnan K; von Moltke LL; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2001 Feb; 29(2):133-40. PubMed ID: 11159802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
